Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
Management of HER2-Low MBC Following First-Line Disease Progression
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Aparna R. Parikh, MD
Expert Viewpoint: Optimizing Breast Cancer Treatment
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Alan Venook, MD
Management of HR+, HER2- High-Risk EBC
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
The Evolving Treatment Landscape for MBC: Emerging Therapies
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.